ImClone and Bristol-Myers Squibb have established an agreement with Merck KgA to co-develop and co-commercialize Erbitux in Japan. The three companies will collaborate on a joint effort to develop and, following regulatory approval, market the drug in Japan for the treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC), as well as for the treatment of any other cancers the parties agree to pursue. BMS and Merck will utilize their respective sales forc...